Menu
Sign In Search Podcasts Charts Entities Add Podcast API Pricing
Podcast Image

AbbottTalks

S1 E4 - Ryan Lakin dives into Abbott's pioneering role in digital health and patient engagement

27 Sep 2023

Description

In the newest episode of AbbottTalks, Ryan Lakin, Divisional Vice President of Digital Solutions, Medical Devices at Abbott, delves deep into the transformative role of digital health solutions in the medical device landscape and emphasizes Abbott's commitment to not just treating the sick but also empowering individuals to maintain optimal health. Lakin shares insights into how Abbott's innovative technologies, like the FreeStyle Libre 2 glucose monitoring system and Lingo, are reshaping patient care by offering real-time data and insights. This proactive approach allows patients to understand their body's reactions to various stimuli, leading to more informed health decisions. Lakin also touches on the challenges of integrating digital tools into healthcare, highlighting the need for evidence-based solutions that genuinely add value. He underscores the importance of simplifying patient pathways, reducing healthcare worker burdens, and enhancing overall patient experiences. As Abbott continues to pioneer in this realm, Lakin speaks to a future where medical devices play a more holistic role in patient care, from prevention to intervention. Listen today to hear more on how Abbott is shaping the future of digital health. Thank you to GlobalMed-MDI for sponsoring this episode. To learn more about how GlobalMed-MDI works with medical device companies, visit www.moldeddevices.com. Thank you for listening to the AbbottTalks Podcast. Click here to subscribe on your favorite podcast player: https://abbotttalks.castos.com/subscribe 

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

No transcription available yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.